Pacific Bio (NASDAQ: PACB) reported Q2 EPS of ($0.21), $0.01 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $30.6 million versus the consensus estimate of $29.89 million.

For earnings history and earnings-related data on Pacific Bio (PACB) click here.